| Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ... The lancet oncology 18 (12), 1688-1700, 2017 | 641 | 2017 |
| Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide … AS Knoop, H Knudsen, E Balslev, BB Rasmussen, J Overgaard, ... Journal of Clinical Oncology 23 (30), 7483-7490, 2005 | 411 | 2005 |
| Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study X Pivot, J Gligorov, V Müller, P Barrett-Lee, S Verma, A Knoop, ... The lancet oncology 14 (10), 962-970, 2013 | 248 | 2013 |
| PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer J Dupont Jensen, AV Laenkholm, A Knoop, M Ewertz, R Bandaru, W Liu, ... Clinical Cancer Research 17 (4), 667-677, 2011 | 227 | 2011 |
| Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study AR Kodahl, MB Lyng, H Binder, S Cold, K Gravgaard, AS Knoop, ... Molecular oncology 8 (5), 874-883, 2014 | 213 | 2014 |
| Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of … X Pivot, J Gligorov, V Müller, G Curigliano, A Knoop, S Verma, V Jenkins, ... Annals of oncology 25 (10), 1979-1987, 2014 | 181 | 2014 |
| Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients AS Knoop, SM Bentzen, MM Nielsen, BB Rasmussen, C Rose Journal of clinical oncology 19 (14), 3376-3384, 2001 | 169 | 2001 |
| Persistence of docetaxel-induced neuropathy and impact on quality of life among breast cancer survivors L Eckhoff, AS Knoop, MB Jensen, M Ewertz European Journal of Cancer 51 (3), 292-300, 2015 | 165 | 2015 |
| PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab JD Jensen, A Knoop, AV Lænkholm, M Grauslund, MB Jensen, ... Annals of oncology 23 (8), 2034-2042, 2012 | 165 | 2012 |
| The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D K Vang Nielsen, B Ejlertsen, S Møller, J Trøst Jørgensen, A Knoop, ... Acta oncologica 47 (4), 725-734, 2008 | 150 | 2008 |
| Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish Breast Cancer Cooperative Group (DBCG) S Cold, M Düring, M Ewertz, A Knoop, S Møller British journal of cancer 93 (6), 627-632, 2005 | 144 | 2005 |
| PAM50 risk of recurrence score predicts 10-year distant recurrence in a comprehensive Danish cohort of postmenopausal women allocated to 5 years of endocrine therapy for … AV Lænkholm, MB Jensen, JO Eriksen, BB Rasmussen, AS Knoop, ... Journal of Clinical Oncology 36 (8), 735-740, 2018 | 141 | 2018 |
| Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer A Knoop, PA Andreasen, JA Andersen, S Hansen, AV Laenkholm, ... British Journal of Cancer 77 (6), 932-940, 1998 | 134 | 1998 |
| A time and motion study of subcutaneous versus intravenous trastuzumab in patients with HER 2‐positive early breast cancer E De Cock, X Pivot, N Hauser, S Verma, P Kritikou, D Millar, A Knoop Cancer medicine 5 (3), 389-397, 2016 | 115 | 2016 |
| Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes KE Olsen, H Knudsen, BB Rasmussen, E Balslev, A Knoop, B Ejlertsen, ... Acta Oncologica 43 (1), 35-42, 2004 | 105 | 2004 |
| Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer L Eckhoff, AS Knoop, MB Jensen, B Ejlertsen, M Ewertz Breast cancer research and treatment 142, 109-118, 2013 | 96 | 2013 |
| ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer JD Jensen, A Knoop, M Ewertz, AV Laenkholm Breast cancer research and treatment 132, 511-521, 2012 | 88 | 2012 |
| HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients B Ejlertsen, MB Jensen, KV Nielsen, E Balslev, BB Rasmussen, ... Journal of Clinical Oncology 28 (6), 984-990, 2010 | 88 | 2010 |
| Correlation between circulating cell‐free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA‐mutated metastatic breast cancer AR Kodahl, S Ehmsen, N Pallisgaard, AMB Jylling, JD Jensen, ... Molecular oncology 12 (6), 925-935, 2018 | 70 | 2018 |
| Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial B Ejlertsen, MK Tuxen, EH Jakobsen, MB Jensen, AS Knoop, I Højris, ... J Clin Oncol 35 (23), 2639-2646, 2017 | 62 | 2017 |
Lesley J. FallowfieldDirector SHORE-C, University of SussexVerified email at sussex.ac.uk
